Cybin to Provide Business Update on February 17, 2021 Conference Call
Cybin Inc. a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will conduct a conference call and webcast to review its financial results and provide a business update as follows: A replay of the conference call will be available for two weeks after the call’s completion by dialing 512-2921 or 317-6671 . The conference ID for the … Date A replay of the conference call will be available for two weeks after the call’s completion by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (International). The conference ID for the replay is 13716476. The archived webcast will be available for 30 days on: www.cybin.com/investor-relations .
Cybin Announces Closing of Upsized Bought Deal Offering
Company Has Raised Nearly CDN$90 Million to Date NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Cybin Inc. a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering including the exercise of the over-allotment option granted to the … Company Has Raised Nearly CDN$90 Million to Date NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering (the “
Cybin Included in First Psychedelic Exchange Traded Fund
Horizons Psychedelic Stock Index ETF Index now trading on the NEO Exchange – Not for distribution to the U.S. news wire services or dissemination in the United States Cybin Inc. a biotechnology company focused on progressing psychedelic therapeutics, today announced that it is among the select companies in the U.S. and Canada to be included in the world’s first exchange-traded fund for psychedelic drug …
Horizons Psychedelic Stock Index ETF Index now trading on the NEO Exchange – Not for distribution to the U.S. news wire services or dissemination in the United States
HIGHLIGHTS Using Kernel’s technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences. The absence of this data has been a limitation in the progression of new molecules targeting neurological disorders. Kernel’s technology opens new frontier in psychedelic therapeutics by acquiring longitudinal brain activity before, during and after a psychedelic experience, enabling .